15,696 Shares in Alkermes plc (NASDAQ:ALKS) Purchased by Cerity Partners LLC

Cerity Partners LLC purchased a new stake in shares of Alkermes plc (NASDAQ:ALKS) in the third quarter, HoldingsChannel.com reports. The institutional investor purchased 15,696 shares of the company’s stock, valued at approximately $439,000.

Several other hedge funds have also bought and sold shares of ALKS. EFG Asset Management North America Corp. lifted its holdings in shares of Alkermes by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 75,864 shares of the company’s stock valued at $1,828,000 after purchasing an additional 359 shares during the last quarter. United Services Automobile Association raised its stake in Alkermes by 3.1% during the second quarter. United Services Automobile Association now owns 13,208 shares of the company’s stock valued at $318,000 after buying an additional 400 shares during the last quarter. Signaturefd LLC boosted its holdings in Alkermes by 51.2% in the second quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after acquiring an additional 480 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in Alkermes by 0.3% in the third quarter. Handelsbanken Fonder AB now owns 220,600 shares of the company’s stock worth $6,175,000 after acquiring an additional 700 shares in the last quarter. Finally, Nicollet Investment Management Inc. grew its stake in shares of Alkermes by 1.7% in the third quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock worth $1,227,000 after acquiring an additional 714 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

Alkermes Trading Up 0.9 %

Shares of NASDAQ:ALKS opened at $31.46 on Monday. The stock’s 50-day simple moving average is $28.32 and its two-hundred day simple moving average is $26.77. The stock has a market capitalization of $5.09 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 1.03 and a beta of 0.49. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $32.88. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. The Goldman Sachs Group dropped their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and issued a $37.00 target price on shares of Alkermes in a research note on Friday, October 25th. Piper Sandler reissued an “overweight” rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Cantor Fitzgerald lowered their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Finally, Mizuho lifted their target price on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.42.

Insider Transactions at Alkermes

In related news, SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the transaction, the senior vice president now directly owns 60,703 shares in the company, valued at approximately $1,769,492.45. The trade was a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Craig C. Hopkinson sold 58,996 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the sale, the executive vice president now owns 83,300 shares in the company, valued at approximately $2,505,664. The trade was a 41.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 83,896 shares of company stock worth $2,526,083 in the last quarter. Company insiders own 4.89% of the company’s stock.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.